| pubmed-article:16948867 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16948867 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:16948867 | lifeskim:mentions | umls-concept:C0664336 | lld:lifeskim |
| pubmed-article:16948867 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:16948867 | lifeskim:mentions | umls-concept:C0062802 | lld:lifeskim |
| pubmed-article:16948867 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:16948867 | pubmed:dateCreated | 2006-9-14 | lld:pubmed |
| pubmed-article:16948867 | pubmed:abstractText | Recently, it was described that an HLA-A24 restricted peptide derived from the survivin splice variant survivin-2B can be recognized by CD8+ cytotoxic T-cells. The identification of an HLA-A24 epitope is critical for survivin-based immunotherapy as HLA-24 is the most frequent HLA allele in Asia. Consequently, this survivin-2B epitope is already a target in a clinical study in patients with advanced or recurrent colorectal cancer expressing survivin. However, the splice variant survivin-2B has been described to be pro-apoptotic, and is only expressed at low levels in most malignant tissues. Furthermore, survivin-2B expression are significantly decreased in later tumor stages and inversely correlated with tumor differentiation and invasion. Consequently, survivin is a more general vaccination candidate than the splice variant survivin-2B. Here, we on the basis of spontaneous immune responses in HLA-A24+ cancer patients describes that a HLA-A24-restricted survivin epitopes does indeed exist. Consequently, this epitope is an attractive target for the ongoing survivin-based peptide immunotherapy against cancer. | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16948867 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16948867 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:16948867 | pubmed:issn | 1479-5876 | lld:pubmed |
| pubmed-article:16948867 | pubmed:author | pubmed-author:BeckerJürgen... | lld:pubmed |
| pubmed-article:16948867 | pubmed:author | pubmed-author:thor... | lld:pubmed |
| pubmed-article:16948867 | pubmed:author | pubmed-author:AndersenMads... | lld:pubmed |
| pubmed-article:16948867 | pubmed:author | pubmed-author:SoerensenRikk... | lld:pubmed |
| pubmed-article:16948867 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:16948867 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:16948867 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16948867 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16948867 | pubmed:pagination | 38 | lld:pubmed |
| pubmed-article:16948867 | pubmed:dateRevised | 2010-9-15 | lld:pubmed |
| pubmed-article:16948867 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16948867 | pubmed:articleTitle | HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer. | lld:pubmed |
| pubmed-article:16948867 | pubmed:publicationType | Editorial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16948867 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16948867 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16948867 | lld:pubmed |
